Therapeutic dendritic-cell vaccine for simian AIDS.

Memory CD8 T-cell differentiation during viral infection. J Virol (2004) 6.75

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 5.07

DC-based cancer vaccines. J Clin Invest (2007) 3.81

Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol (2004) 3.12

Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nat Immunol (2004) 2.64

Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol (2005) 2.06

International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03

Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology (2007) 1.46

HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology (2004) 1.36

CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol (2004) 1.25

Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood (2005) 1.16

Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol (2010) 1.13

Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med (2009) 1.13

Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood (2005) 1.11

Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog (2008) 1.10

Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med (2003) 1.09

In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS One (2009) 1.09

Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-cell origin. J Virol (2003) 1.08

HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol (2015) 1.06

Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol (2006) 1.05

Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol (2006) 1.03

Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J Virol (2005) 1.03

Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J Virol (2005) 1.02

Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One (2012) 1.01

Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol (2004) 0.99

HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci U S A (2009) 0.98

SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans. Retrovirology (2013) 0.96

HIV-1 and the hijacking of dendritic cells: a tug of war. Springer Semin Immunopathol (2005) 0.96

A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retroviruses (2008) 0.95

Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother (2013) 0.95

Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine. Nat Med (2003) 0.94

A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells. J Virol (2008) 0.93

Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines (2013) 0.92

Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors. Acta Biomater (2008) 0.92

A cure for AIDS: a matter of timing? Retrovirology (2013) 0.92

Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine (2010) 0.91

Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology (2012) 0.90

Generation of feline dendritic cells derived from peripheral blood monocytes for in vivo use. Clin Diagn Lab Immunol (2005) 0.89

Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr (2009) 0.87

Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model. Front Immunol (2014) 0.86

Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection. Vet Immunol Immunopathol (2009) 0.85

Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clin Dev Immunol (2012) 0.85

Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine. J Virol (2005) 0.85

A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One (2010) 0.85

Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology (2007) 0.85

Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy. Open AIDS J (2014) 0.83

Therapeutic immunization for HIV. Springer Semin Immunopathol (2006) 0.83

Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus. Clin Vaccine Immunol (2008) 0.81

Identification and characterization of macaque CD89 (immunoglobulin A Fc receptor). Immunology (2004) 0.81

DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells. Vaccine (2011) 0.80

Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine (2010) 0.80

Inactivated simian immunodeficiency virus-pulsed autologous fresh blood cells as an immunotherapy strategy. J Virol (2008) 0.79

Immunotherapy with internally inactivated virus loaded dendritic cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course. Retrovirology (2008) 0.79

Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia. Vaccine (2008) 0.78

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines (Basel) (2016) 0.77

Simian immunodeficiency virus interactions with macaque dendritic cells. Adv Exp Med Biol (2013) 0.77

Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol (2009) 0.77

Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. Vaccine (2011) 0.77

Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance. PLoS One (2014) 0.77

Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells. Pharmaceuticals (Basel) (2012) 0.76

SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques. Retrovirology (2011) 0.76

Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses. Clin Dev Immunol (2012) 0.76

Study on biological characters of SGC7901 gastric cancer cell-dendritic cell fusion vaccines. World J Gastroenterol (2006) 0.75

Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses. PLoS One (2014) 0.75

Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine (2014) 0.75

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol (2005) 2.50

The biological meaning of anti-HBC positive result in blood donors: relation to HBV-DNA and to other serological markers. Rev Inst Med Trop Sao Paulo (2003) 1.56

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48

Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer (2007) 1.40

Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol (2005) 1.13

Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China. AIDS Res Hum Retroviruses (2008) 1.04

Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China. AIDS (2009) 1.03

Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 0.99

What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int (2009) 0.98

Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging (2007) 0.98

Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. J Acquir Immune Defic Syndr (2004) 0.98

Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. Eur Urol (2009) 0.97

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol (2002) 0.87

Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res (2002) 0.86

Variability of bio-clinical parameters in Chinese-origin Rhesus macaques infected with simian immunodeficiency virus: a nonhuman primate AIDS model. PLoS One (2011) 0.86

Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer (2008) 0.85

Molecular epidemiology of human immunodeficiency virus type 1 in Guangdong province of southern China. PLoS One (2012) 0.85

Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Drugs R D (2011) 0.82

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood (2004) 0.81

Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria. Prostate (2007) 0.80

Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial. Cancer (2010) 0.79

Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial. Cancer (2002) 0.78

Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation. Cancer (2008) 0.77

Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood (2003) 0.76

Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer (2008) 0.76

T cell survival/proliferation reconstitution by trifluoperazine in human immunodeficiency virus-1 infection. Virology (2003) 0.76

Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation. Leuk Lymphoma (2012) 0.75

Effect of Ganoderma Lucidum Preparation on the Behavior,Biochemistry,and Autoimmune Parameters of Mouse Models of APP/PS1 Double Transgenic Alzheimer's Disease. Chin Med Sci J (2017) 0.75

Determination of phenolic preservatives in gelatin and vacant capsules for medicine use by ion-suppression reversed-phase high performance liquid chromatography. J Pharm Biomed Anal (2005) 0.75